Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 2, keine Gesamtzahl für „Poherdy“
Suchtreffer
Begriffe & Kennungen
Poherdy · 4.8 · Febrile neutropenia In the pivotal trial CLEOPATRA, the majority of patients in both treatment groups experien
Eintrag öffnenPoherdy · 4.8 · Hypersensitivity reactions/anaphylaxis In the pivotal trial CLEOPATRA in metastatic breast cancer, the overall
Eintrag öffnenPoherdy · 4.8 · In APHINITY, the incidence of symptomatic heart failure (NYHA class III or IV) with a LVEF decline of at least
Eintrag öffnenPoherdy · 4.8 · In addition, ADRs reported in the post-marketing setting are included in Table 2. As pertuzumab was used with
Eintrag öffnenPoherdy · 4.8 · In the APHINITY trial, a higher incidence of diarrhoea was reported in the Pertuzumab-treated arm (71.2%) comp
Eintrag öffnenPoherdy · 4.8 · In the APHINITY trial, febrile neutropenia occurred in 12.1% of Pertuzumab-treated patients and 11.1% of place
Eintrag öffnenPoherdy · 4.8 · In the APHINITY trial, the adverse event of rash occurred in 25.8% of patients in Pertuzumab arm vs. 20.3% of
Eintrag öffnenPoherdy · 4.8 · In the NEOSPHERE trial, 8.4% of patients treated with neoadjuvant Pertuzumab, trastuzumab and docetaxel experi
Eintrag öffnenPoherdy · 4.8 · In the NEOSPHERE trial, diarrhoea occurred in 45.8% of patients treated with neoadjuvant Pertuzumab, trastuzum
Eintrag öffnenPoherdy · 4.8 · In the NEOSPHERE trial, rash occurred in 40.2% of patients treated with neoadjuvant Pertuzumab, trastuzumab an
Eintrag öffnenPoherdy · 4.8 · In the NEOSPHERE trial, the incidence of NCI-CTCAE v.3 Grade 3-4 neutropenia was 74.5% in patients treated wit
Eintrag öffnenPoherdy · 4.8 · In the TRYPHAENA trial, rash occurred in 36.8% of patients treated with neoadjuvant Pertuzumab + TCH and 20.0%
Eintrag öffnenPoherdy · 4.8 · In the neoadjuvant and adjuvant trials, hypersensitivity/anaphylaxis events were consistent with those observe
Eintrag öffnenPoherdy · 4.8 · In the neoadjuvant period of the BERENICE trial, the incidence of NYHA Class III/IV symptomatic LVD (congestiv
Eintrag öffnenPoherdy · 4.8 · In the neoadjuvant trial NEOSPHERE, in which patients received 4 cycles of pertuzumab as neoadjuvant treatment
Eintrag öffnenPoherdy · 4.8 · Infusion-related reactions (IRRs) An infusion-related reaction was defined in the pivotal trials as any event
Eintrag öffnenPoherdy · 4.8 · Laboratory abnormalities In the pivotal trial CLEOPATRA in metastatic breast cancer, the incidence of NCI-CTCA
Eintrag öffnenPoherdy · 4.8 · Left ventricular dysfunction (LVD)
Eintrag öffnenPoherdy · 4.8 · Overall, the majority of hypersensitivity reactions were mild or moderate in severity and resolved upon treatm
Eintrag öffnenPoherdy · 4.8 · Rash In the pivotal trial CLEOPATRA in metastatic breast cancer, rash occurred in 51.7% of Pertuzumab- treated
Eintrag öffnen